{"filing":{"accession_number":"0001193125-26-371260","cik":"0001420565","ticker":"RNTX","company_name":"Rein Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-27","report_date":"2026-08-21","primary_document":"d154403d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312526371260/d154403d8k.htm"},"events":[{"id":30003,"run_id":27500,"accession_number":"0001193125-26-371260","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.99,"summary":"Rein Therapeutics received a formal notice of delisting from Nasdaq on August 21, 2026, for failing to maintain the minimum bid price of $1.00 per share under Rule 5550(a)(1). The company has 180 days (until February 17, 2027) to regain compliance or face suspension and delisting procedures. This is a direct and material delisting risk disclosure under Item 3.01.","company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","filing_date":"2026-08-27","form":"8-K","submitted_at":null,"items":[{"id":32480,"accession_number":"0001193125-26-371260","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.99,"reasoning":"Rein Therapeutics received a formal notice of delisting from Nasdaq on August 21, 2026, for failing to maintain the minimum bid price of $1.00 per share under Rule 5550(a)(1). The company has 180 days (until February 17, 2027) to regain compliance or face suspension and delisting procedures. This is a direct and material delisting risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:07:37.325594+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32480,"accession_number":"0001193125-26-371260","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.99,"reasoning":"Rein Therapeutics received a formal notice of delisting from Nasdaq on August 21, 2026, for failing to maintain the minimum bid price of $1.00 per share under Rule 5550(a)(1). The company has 180 days (until February 17, 2027) to regain compliance or face suspension and delisting procedures. This is a direct and material delisting risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:07:37.325594+00:00","company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","filing_date":"2026-08-27"}]}